急性髓细胞白血病CD7、CD34、CD56、P170的表达对完全缓解率的影响

已有文献报道ＣＤ7、ＣＤ3 4、ＣＤ56、Ｐ170 各自的表达与预后有关[1 5] 。但此四种单抗联合表达对预后的影响报道较少。现将我院 1995～ 1999年检测的 2 13例初诊急性髓系白血病(ＡＭＬ)以上 4种分化抗原的单表达和联合表达对完全缓解(ＣＲ)率的影响分析如下。一、材料与方法1 标本来源 :门诊及住院的 2 13例患者 ,经形态、免疫、部分有遗传及细胞组织化学联合诊断为ＡＭＬ。其中男 115例 ,女 98例 ,年龄 1 5～ 82岁 ,中位年龄 31 5岁。2 试验方法及试剂 :(1)白血病细胞分化抗原测定 :取骨髓单个核细胞 ,间接或直接单克隆抗体标记后 ,用…     

CD7阳性急性髓细胞白血病免疫表型及临床特点

随着系列单克隆抗体的应用，白血病细胞免疫分型的广泛开展及其研究的深入，伴有ＣＤ７抗原表达的急性髓细胞白血病（ＣＤ＋７ＡＭＬ）不断被发现。有学者认为ＣＤ＋７ＡＭＬ是一类独特的急性髓细胞白血病亚型，具有与不伴有ＣＤ７抗原表达的急性髓细胞白血病（ＣＤ－７Ａ...     

CD7^＋急性髓细胞性白血病临床及实验室特征分析

CD7抗原是T细胞性急性淋巴细胞性白血病(acute lymphoblastic leukemia,T-ALL)最敏感的检测指标之一,但其特异性不强,在10%~20%的急性髓细胞性白血病(acute myeloid leukemia,AML)中也有表达[1~2],且AML中CD7+常与多药耐药相关,提示疾病恶性度高、预后差[3~5]。本文报道本院新近收治的1例CD7+AML并复习已知文献,对CD7抗原在AML中的表达及其临床意义进行总结。临床资料患者男性,51岁。2005年11月21日因“低热、乏力、面色苍白1月余”入院。既往史及体格检查均无特殊。入院后查肝功能、肾功能、电解质、尿常规、粪常规及出凝血功能…     

急性髓细胞白血病CD34抗原与干细胞白血病基因表达及其意义

CD34抗原是造血干细胞的表面标志,随着造血干细胞分化、成熟而逐渐消失;干细胞白血病(SCL)基因也表达于造血干细胞中,它在维持造血干细胞增殖分化过程中起着重要作用,并随着造血干细胞的分化成熟而消失.CD34抗原与SCL基因在急性髓细胞白血病(AML)中有所表达,它们与AML的临床特征及预后存在一定关系[1,2],但也存在争论,国内报道较少.我们对167例AML进行免疫分型,应用逆转录-聚合酶链反应(RT-PCR)进行SCL基因检测,同时结合AML临床表现、血流学特点、治疗效果进行分析.     

CD40抗原和生存素基因在急性髓性白血病细胞中表达及其临床意义

目的探讨急性髓性白血病(AML)细胞的CD40抗原和抗凋亡基因生存素(survivin)mRNA表达及其临床意义。方法应用流式细胞仪和逆转录-PCR方法检测48例初治AML患者细胞的CD40抗原和抗凋亡基因survivin mRNA表达,并结合AML患者临床特征进行分析。结果(1)48例AML患者中25例(52．1％)表达CD40抗原,35例(72．9％)表达survivin mRNA。(2)CD40^ AML组中脾肿大、血小板减少和高白细胞白血病的发生率明显高于CD40^-AML组(36．0％、8．7％),P=0．025;(72．0％、43．5％),P=0．045;(32．0％、4．4％),P=0．024。(3)survivin mRNA在CD40^ AML和CD40^-AML两组中表达差异无显著性(20／25、15／23),P=0．25,但两组中的survivin mRNA表达均明显高于健康对照组(20／25、6／20),P=0．001;(15／23、6／20),P=0．021;48例AML患者中CD40抗原阳性率低于survivin mRNA阳性率(52．1％、72．9％),P=0．041。(4)survivin^ AML化疗完全缓解(CR)率明显低于survivin^-AML(31．4％、69．2％),P=0．018。结论CD40抗原表达和AML的临床血液学特征存在一定关系;表达抗凋亡基因survivin mRNA是AML患者化疗CR率低的原因之一,可能是影响AML患者预后的因素。     

急性髓细胞白血病遗传学特征与临床特征分析

目的 :探讨急性髓细胞白血病(AML)患者的分子遗传学特征及其与临床特征的关联性。方法 :采用骨髓短期培养和G显带技术对103例AML患者进行染色体核型分析,并通过PCR技术对其基因突变、融合基因等进行检测。结果:在103例患者样本中所检测到的FMS样酪氨酸激酶3基因的内部串联重复(FLT3-ITD)突变和酪氨酸激酶结构域点突变(FLT3-TKD)、核磷蛋白1(NPM1)基因突变、神经母细胞瘤RAS癌(NRAS)基因突变、异柠檬酸脱氢酶1(IDH1)基因突变、CCAAT/增强子结合蛋白α(CEBPA)基因突变、人类原癌基因C-KIT突变的发生率分别为14.3%、3.3%、14.3%、12.4%、5.6%、10.6%和18.8%;NPM1突变阳性患者较阴性患者骨髓幼稚细胞比例高(P=0.0105),FLT3-ITD突变阳性患者较阴性患者的病死率低(P=0.0285),而C-KIT突变阳性患者较阴性患者的病死率高(P=0.0255)。结论:AML患者的分子遗传学特征细化了基于核型的AML危险度分层,其中FLT3-ITD、NPM1、C-KIT突变与患者的临床特征有关联。     

41例急性髓细胞白血病患者的细胞遗传学分析

目的了解急性髓细胞白血病的细胞遗传学特征及其与预后的关系。方法对41例以FAB分类标准确诊的AML初发患者的细胞遗传学资料进行回顾性分析,应用骨髓细胞短期培养法制备染色体标本,以R显带技术进行核型分析。结果共检出异常核型16例（39．0％）,单纯数目异常的有2例,染色体结构异常的12例,其余2例同时有数目及染色体结构异常。本组中最常见的结构异常为t（15;17）,t（8;21）。结论细胞遗传学对急性髓细胞白血病的诊断具有重要的意义,特别是与FAB分型具有特异性的t（15;17）,t（8;21）染色体异常对急性白血病的诊断具有决定意义。     

急性髓系白血病骨髓单个核细胞CD11a的表达及临床意义

目的:探讨淋巴细胞功能相关抗原-1(LFA-1)的α链CD11a在急性髓系白血病(AML)的表达情况及临床意义。方法:采用免疫酶标ABC法检测25例初治AML患者和8例血液系统非恶性肿瘤患者为对照的骨髓单个核细胞CD11a的表达,并追踪观察AML患者的疗效。结果:CD11a在AML患者骨髓单个核细胞的表达率(37.02±13.30)%,明显低于对照组(87.13±5.38)%(P<0.05)。化疗后未缓解组AML患者发病时骨髓单个核细胞CD11a的表达率(47.09±10.55)较完全缓解组(29.11±9.36)%高(P<0.05)。结论:CD11a在AML患者骨髓单个核细胞表达异常,可能与白血病细胞逃脱机体免疫监控及从造血微环境释出有关。检测AML患者骨髓单个核细胞CD11a的表达水平对AML的预后判断有一定意义。     

老年CD+7急性髓系白血病生物学特征及其临床意义

目的 研究老年CD7抗原阳性急性髓性白血病（CD^＋7AML）的临床生物学特征。方法 对98便初治老年AML进行细胞形态学、免疫表型、多药耐药P糖蛋白（P120）、细胞遗传学核型分析，并采用常规AML方案诱导治疗，判定疗效。结果 老年AML中CD7阳性表达率28.57%（28/98）,28例CD^＋7老年AML（M/F，20/8）的FAB分型结果为：M03例、M13例、M2a6例、M4a2例、M4b1例、M5a1例、M5b9例。CD^＋7老年AML患者外周血白细胞计数（53.80 vs 25.21 P=0.001）、原始细胞比例（69.00% vs 41.02% P=0.001）及P-糖蛋白表达显著增高（67.85 vs 28.57 P=0.001）,肝脏肿大（46.10% vs 23.50% P=0.044）和髓外白血病易发（28.57% vs 2.78% P=0.001）,且对常规化疗反应差，预后不良，完全缓解率亚型，常提示预后不良，建议监测初诊AML患者CD7表达。     

Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia

Debate exists over whether CD7 expression indicates an unfavourable prognosis in de novo acute myeloid leukaemia (AML). Meanwhile, the type of cytogenetics is a strong prognostic factor in AML. We analysed 256 de novo adult AML cases and found that the proportion of CD7+ cases increased stepwise from the cases with favourable cytogenetics to the cases with intermediate and unfavourable cytogenetics (3 out of 69 cases, 51 out of 140 cases and 25 out of 47 cases respectively, P < 0.0001). CD7-positivity adversely affected the survival only in the cases with unfavourable cytogenetics (P < 0.03). We recommend that CD7 expression in AML be interpreted in association with the cytogenetics.     

Biologic and clinical significance of CD7 expression in acute myeloid leukemia

CD7 antigen, a T-cell lineage associated antigen, is expressed in a minority of patients with acute myeloid leukemia (AML). The biologic and clinical significance of this finding is not clearly established. In this retrospective study of patients with de novo acute myeloid leukemia, we have identified CD7 expression and analyzed its association with markers expressed early in hemopoietic ontogeny and clinical parameters. Among 60 consecutive AML patients, we found six (10%) expressing CD7 on leukemic cells. There were five males and one female and the mean age was 59.6 years (age range: 32–76 years) with no demographic peculiarities. The FAB subtypes were: M0 (2), M1 (1), M2 (1), and M4 (2). CD7 expression was associated with immature antigens CD34, HLA-DR, and terminal deoxynucleotidyl transferase (TdT) and antigen receptor gene rearrangements (rearrangements of T-cell receptor gamma chain in 6/6 and immunoglobulin heavy chain in 2/6). Hepatomegaly was present in three and this was associated with splenomegaly with lymphadenopathy in one patient. Mediastinal or central nervous system involvement was absent. Complete remission was achieved in two patients with standard chemotherapy; one of these is in remission and alive (5 years later), while one died following relapse 9 months later. Three patients had significantly lower response to standard therapeutic regimen (two died during induction and one died 7 months later without ever achieving complete remission). One patient has been excluded in determining the prognostic significance of CD7 due to early death. Our results suggest origin of CD7+ AML from early hemopoietic precursors and indicate biologic aggressiveness in a significant proportion of patients. We suggest evaluation of CD7 in all patients with AML at the time of diagnosis in view of poor clinical outcome. Am. J. Hematol. 58:278–284, 1998. © 1998 Wiley-Liss, Inc.     

CD7+CD56+双阳性急性髓系白血病临床生物学特征

目的：探讨CD7^＋CD56^＋急性髓系白血病（AML）的临床生物学意义。方法：对25例初治CD7^＋CD56^＋AML患者进行细胞学形态、免疫表型、多药耐药P糖蛋白（PgP）检测，临床观察、并常规采用HAE方案诱导治疗，判定疗效，并随机选择66例CD7^-CD56^-AML患者进行对照。结果：CD7^＋CD56^＋AML阳性率4．08％（25／612）。CD7^＋CD56^＋AML在FAB分型中以M0、M1、M5、M7多见。与CD7^-CD56^-AML组比较CD7^＋CD56^＋AML具有高血红蛋白含量（89．29：75．62g／L，P〈0．05），高表达PgP（78．26％：34．85％，P〈0．01）和CD34表达（72．00％：45．45％，P〈0．05）等特征；此外，CD7^＋CD56^＋AML患者中枢神经系统浸润现象明显（36．00％：3．27％，P〈0．01），CD7CD56共表达与年龄、性别、白细胞计数、血小板计数、及外周血幼稚细胞数无关，也不影响完全缓解率和无病生存时间（均P〉0．05）。结论：CD7^＋CD56^＋AML具有独特的临床生物学特征，较少贫血，高表达PgP和CD34，常伴有中枢神经系统浸润。     

Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0

Myeloid/natural killer (NK) cell precursor acute leukemia is an entity of acute leukemia characterized by poor prognosis and a CD7+CD56+ myeloid antigen+ phenotype without light-microscopic myeloperoxidase reactivity. This disease shares several clinical characteristics with acute myeloid leukemia (AML) M0. To clarify the relationship between these 2 leukemias, we analyzed 105 cases of AML M0. Among them, 17 were CD7+ and CD56+, 77 were negative for either antigen, and 11 could not be determined. CD7+CD56+ AML M0 showed onset at significantly lower patient age (median 46 versus 63 years, P = .004). The disease localization and the hematological manifestations were significantly different: CD7+CD56+ AML showed more frequent extramedullary involvement, fewer circulating leukemic blasts, less anemia, and less thrombocytopenia than did AML M0. The cytogenetic aberrations were also unique, because no 5q abnormalities were found in CD7+CD56+ M0. The prognosis of CD7+CD56+ M0 was poor in patients younger than 46 years (P = .03). Multivariate analysis showed that the CD7+CD56+ phenotype was a significant prognostic factor for AML M0, as well as age, circulating blast percentage, and chromosome 5 abnormalities These findings suggest that AML M0 consists of heterogeneous subgroups to be managed separately, and CD7+CD56+ M0 constitutes a distinct subtype of AML M0.     

Clinical importance of cytogenetics in acute myeloid leukaemia

Acquired chromosome aberrations are present in the marrow of most patients with acute myeloid leukaemia (AML) at diagnosis. Cytogenetically, AML is a very heterogeneous disease with over 160 structural chromosome abnormalities observed recurrently to date. Molecular dissection of many reciprocal translocations and inversions has resulted in cloning of the genes involved in leukaemogenesis. Some recurrent aberrations and the resulting gene rearrangements, namely inv(16)/t(16;16) and CBFbeta- MYH11, t(8;21) and CBFA2-CBFA2T1, t(15;17) and PML-RARalpha, and rearrangements of band 11q23 and the MLL gene, are now used to help define distinct disease entities within AML in the new World Health Organization classification of haematological malignancies. Moreover, cytogenetic abnormalities, whether molecularly characterized or not, are among the most important, independent prognostic factors in AML, and are being used in the management of AML patients. This review presents current information on chromosome abnormalities in AML, and on associations between karyotype and clinical characteristics and outcome of AML patients.     

急性胰腺炎患者外周血CD14^+CD16^+单核细胞表达B7-H2的临床意义

背景急性胰腺炎(acute pancreatitis,AP)是常见的急腹症,不同类型预后不同.AP的免疫应答和失衡免疫与其严重程度有关,炎症因子和相关免疫细胞在AP发病机制中至关重要,因而寻找炎症细胞和新炎症免疫因子对精准治疗AP具有重要意义.目的探讨AP患者外周血CD14^+CD16^+单核细胞表达B7-H2的临床意义.方法A P患者63例[轻度A P(m i l dA P,M A P)25例、中度AP(moderately severe AP,MSAP)20例、重度AP(severe AP,SAP)18例],对照组为健康体检者20例,采用流式细胞仪检测CD14^+CD16^+细胞亚群上B7-H2表达情况,评价其与胰腺炎严重程度关联性及临床意义.结果AP患者发病24hCD14^+CD16^+细胞B7-H2出现异常高表达,显著高于健康对照组(t=11.10,P<0.001);A P各组B 7-H 2在C D 14^+C D 16^+细胞膜上表达明显高于CD14^+C D16^-细胞膜上表达(P<0.01);SAP组CD14^+C D 16^+和CD14^+C D 16^-细胞B7-H2表达(373.30±89.72和78.62±13.05)最高,M S A P组(279.55±76.95/44.92±12.44)其次,均高于M A P组(181.15±35.75/23.32±4.28),各组两两比较差异有显著性(P<0.01);MAP组、MSAP组发病24 h、48 h、72hCD14^+CD16^+和CD14^+CD16^-单核细胞膜B7-H2动态表达差异无显著性(P>0.05),然而,SAP组无论C D14^+C D16^+还是CD14^+C D16^-细胞膜B7-H2表达24h、48h、72h均呈明显上升趋势,差异有显著性(P<0.05).结论CD14^+CD16^+和CD14^+CD16^-单核细胞膜B7-H2在AP患者体内高表达,与AP严重程度密切相关,且SAP呈动态升高变化;同时B7-H2在AP患者CD14^+CD16^+单核细胞膜表达较CD14^+CD16^-单核细胞明显升高,为进一步认识AP免疫应答和失衡提供了新的线索,为AP精准靶向治疗提供参考.     

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population‐based series of acute myeloid leukaemia

Unsuccessful cytogenetics (UC) in patients with acute myeloid leukaemia (AML) treated on different SWOG trials was recently reported to be associated with increased age and dismal outcome. To ascertain whether this holds true also in unselected patients with AML, we retrieved all cytogenetic reports in cases from the population‐based Swedish AML Registry. Between 1997 and 2006, 1737 patients below 80 yr of age without myelosarcoma or acute promyelocytic leukaemia received intensive treatment. The frequencies of UC and unperformed cytogenetics (UPC) were 2.1% and 20%, respectively. The early death rates differed between the cytogenetic subgroups (P = 0.006) with the highest rates in patients with UC (14%) and UPC (12%) followed by high‐risk (HR) AML, intermediate risk (IR) and standard risk (SR) cases successfully karyotyped (8.6%, 5.9%, and 5.8%, respectively). The complete remission rate was lower in UC and UPC and HR compared with the other risk groups (P < 0.001). The overall five‐year survival rates were 25% for UC and 22% for UPC, whereas the corresponding frequencies for SR, IR and HR AML patients without UC and UPC were 64%, 31% and 15%, respectively. In conclusion, lack of cytogenetic data translates into a poor prognosis.     

CD7-positive acute myeloid leukemia: further evidence of cellular immaturity

Summary Among 63 cases of acute myeloid leukemia (AML), 14 were found to express the CD7 antigen, a cell surface marker usually found at an early stage during T lineage differentiation. The CD7-positive AML cases consisted of 5 cases of M1, 3 cases of M2, 3 cases of M4, 1 case of M5, 1 case of M6 and 1 case of M7. Among these 63 cases, the proportion of blast cells expressing the CD34 antigen was examined. The proportion of CD34-stained cells among the CD7-positive AML cases, although varying, was significantly larger than that among the CD7-negative AML cases (P<0.05). As the CD34 antigen was expressed on hematopoietic progenitor cells and was considered to reflect an early hematopoietic stage, the high proportion of cells expressing CD34 among the CD7-positive AML cases may support the notion that CD7-positive AML cells are immature.Abbreviations AML acute myeloid leukemia - CD clusters of differentiation Partly supported by grants-in-aid from the Ministry of Education, Culture and Science of Japan (03252102, 63015063, 02256102, and 03670325) and from theFukuoka Anti-Cancer Society